Paper Details

  1. Home
  2. Paper Details

Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia.

Author: CarpenterWilliam T, ConleyRobert R, KellyDeanna L, RichardsonCharles M, TammingaCarol A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A randomized, double-blind crossover study of clozapine (450 mg/day) vs. high doses of olanzapine (50 mg/day) in patients with treatment-resistant schizophrenia showed that 20% of clozapine-treated patients responded, while no olanzapine-treated patients responded. Olanzapine was associated with more anticholinergic effects (e.g., dry mouth, blurry vision) and weight gain. Clozapine was associated with higher rates of sialorrhea, sweating, dyspepsia, and lethargy.
Paper Details　
Original Abstract of the Article :
Patients with treatment-resistant schizophrenia pose a major challenge to caregivers since only clozapine is documented as having superior efficacy in this population. Although olanzapine is similar to clozapine in structure and receptor profile, it has not been proven to have superior efficacy for ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1023/b:acli.0000008171.90644.f8

データ提供：米国国立医学図書館（NLM）

Treatment-Resistant Schizophrenia: A Challenging Desert

Treatment-resistant schizophrenia is a challenging condition, like a desert storm that leaves those affected feeling lost and isolated. This research compares the effectiveness of two antipsychotic drugs, [clozapine] and [olanzapine], in patients with treatment-resistant schizophrenia, a population for whom finding effective treatment options can be particularly difficult.

A Comparison of Antipsychotics: Seeking Relief in the Desert

The researchers conducted a study involving 13 patients with treatment-resistant schizophrenia, comparing high doses of [olanzapine] to [clozapine]. They found that [clozapine] was more effective in achieving a response, while [olanzapine] was associated with more anticholinergic side effects, such as dry mouth and blurry vision. Both drugs were associated with weight gain, but [olanzapine] was linked to greater weight gain.

Navigating the Desert of Treatment-Resistant Schizophrenia

This research highlights the importance of finding the right treatment approach for individuals with treatment-resistant schizophrenia. The findings suggest that [clozapine] might be a more effective option for this population, but it's crucial to carefully weigh the potential benefits and risks of each medication, considering individual patient needs and preferences.

Dr.Camel's Conclusion

The desert of treatment-resistant schizophrenia is a challenging landscape, but understanding the nuances of different antipsychotic medications can help us navigate this terrain more effectively. This study sheds light on the potential benefits and drawbacks of both [clozapine] and [olanzapine], emphasizing the need for personalized treatment approaches to find the best path toward recovery.

Date :
  1. Date Completed 2004-08-10
  2. Date Revised 2019-11-08
Further Info :

Pubmed ID

14971863

DOI: Digital Object Identifier

10.1023/b:acli.0000008171.90644.f8

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.